Answers are grounded in this paper and cite their sources.
The adoptive transfer of redirected T cells that are engineered by gene transfer to express receptors that target tumor-associated molecules and signal T cell effector functions is emerging as an effective modality for cancer therapy, and holds promise for treating a broad range of malignancies, including those commonly managed with autologous or allogeneic hematopoietic stem cell transplantation (HSCT). In this review, we focus on current issues for engineering T cells with chimeric antigen receptors (CARs) that are specific for molecules on hematologic malignancies, and discuss the prospects and challenges for using such T cells either alone or as an adjunct to HSCT to reduce the unacceptably high rates of relapse associated with this procedure [1].
No takes yet. Share an insight, caveat, or question.
Riddell et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: